Kansteiner, In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary, Fierce Pharma (2025)
For both companies, the aggressive pricing reset marks the beginning of a new phase in the obesity-drug battle
doi:10.2147/JMDH.S419245 Karagiannis T, Tsapas A, Athanasiadou E, et al
These include: Nausea (reported in a significant proportion of participants, particularly during dose escalation) Vomiting and diarrhoea Constipation and abdominal discomfort Decreased appetite , which, whilst contributing to weight loss, can occasionally lead to inadequate nutritional intake Most gastrointestinal effects were described as mild to moderate in severity and tended to diminish over time
Fiber supplements can address constipation
In March 2026, Lilly also reported positive Phase 3 data for retatrutide in type 2 diabetes